Therapeutically targetable oncogenes in NSCLC include mutations or alterations in Epidermal growth factor receptor mutations (EGFRms), Kirsten rat sarcoma virus mutations (KRASms), Anaplastic lymphoma kinase (ALK), B-Raf murine sarcoma viral oncogene homolog B (BRAFm), ROS proto-oncogene 1(ROS1), Mesenchymal-epithelial transition factor (MET), Human epidermal growth factor receptor-2 (erbB-2, or HER2), Rearranged during transfection (RET), and Neurotrophic tyrosine receptor kinase 1,2, and 3 (NTRK). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.